Neurogene Inc.
NasdaqGM NGNE
Neurogene Inc. Total Assets for the quarter ending September 30, 2024
Neurogene Inc. Total Assets is NA for the quarter ending September 30, 2024. Total assets are the total value of all assets owned by a company, representing its resources.
-
Neurogene Inc. Total Assets for the quarter ending September 30, 2023 was USD 89.59 M, a -29.22% change year over year.
-
Neurogene Inc. Total Assets for the quarter ending September 30, 2022 was USD 126.58 M.
Key data
| Date | Total Assets | Current Liabilities | Total Non-Current Liabilities | Shareholders' Equity |
|---|
Market news
Loading...
NasdaqGM: NGNE
| CEO | Dr. Rachel L. McMinn Ph.D. |
| IPO Date | March 7, 2014 |
| Location | United States |
| Headquarters | 535 W 24th Street |
| Employees | 91 |
| Sector | Health Care |
| Industries | |
Description
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email